Line 13: |
Line 13: |
| }} | | }} |
| | | |
− | ==Morphology==
| |
− | *Fragile, enveloped RNA viruses with roughly spherical spike proteins
| |
− | *Genome has 3 genes:
| |
− | **''gag'': group-specific antigen coding gene, encodes capsid proteins
| |
− | **''pol'': encodes reverse transcriptase (RT) and integrase
| |
− | **''env'': encodes envelope spikes, and can be used in diagnosis and subunit vaccines
| |
− | *Both ends of genome show a promoter (LTR: long terminal repeat)
| |
− |
| |
− | ==Antigenicity==
| |
− | *Group-specific antigens (gag's) are shared by all isolates of each virus
| |
− | **This can be exploited by diagnostic tests
| |
− | *Lentiviruses show variation by mutation, making vaccination difficult
| |
− |
| |
− | ==Virulence and Pathogenesis==
| |
− | *Replication involves integrating into the host cell genome:
| |
− | **'''Uncoating''' to release RNA and RT
| |
− | **+RNA '''transcribed''' to -DNA by RT
| |
− | **-DNA becomes circular dsDNA and is '''integrated''' into host chromosome by integrase
| |
− | **DNA '''codes''' for viral proteins using cellular organelles and enzymes
| |
− | **Because of this technique, virus replication is much '''slower''', and retroviruses can remain '''latent'''
| |
− | *Tumor production takes 2 forms:
| |
− | **Viruses can carry oncogenes within their genome --> tumor production occurs quickly
| |
− | **Insertion of the viral LTR switches on proto-oncogenes in the host cell genome --> tumor production can take years
| |
| | | |
| | | |
| [[Category:Viral Organisms]] | | [[Category:Viral Organisms]] |
| [[Category:To_Do_-_Clinical/Viruses]] | | [[Category:To_Do_-_Clinical/Viruses]] |